Protein Potential LLC Awarded $3 Million U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Vaccine Targeting Plasmodium vivax, a Neglected Cause of Malaria

ROCKVILLE, Maryland, April 19, 2010 - Protein Potential LLC has received support from the National Institute of
Allergy and Infectious Diseases (NIAID) of the NIH in the form of a Phase II
Small Business Innovation Research (SBIR) Grant. The three-year award
totaling approximately US$3 million will support translational research to
develop a vaccine for the prevention of malaria caused by the parasite
Plasmodium vivax. Approximately 40% of the world's population is at risk from
malaria and each year an estimated 1 million people die from the disease. P.
vivax is the world's second most serious cause of malaria, with most of the
greater than 80 million annual cases in Asia, Oceania, and Latin America.
There is growing awareness that a vaccine targeting P. vivax is badly needed
if the goal of malaria eradication is to be achieved. Dr. Pedro Alonso,
Director of the Barcelona Centre for International Health Research and head
of the steering committee for the Malaria Eradication Research Agenda,
states, "The need for effective tools to combat P. vivax malaria cannot be
emphasized enough. The prospects for realizing the goal of malaria
eradication will be substantially improved by a vaccine that prevents P.
vivax infections. Protein Potential's efforts to develop such a vaccine are
an important step in this direction."

Protein Potential's vaccine consists of parts of the P. vivax
circumsporozoite protein (CSP), which covers the parasite surface during the
initial stages of infection. Antibodies against CSP can block critical steps
in the early infection process. "This Phase II SBIR funding will be used to
develop vaccine lots that satisfy manufacturing and quality assurance
criteria necessary to proceed to clinical testing in human subjects," says
Protein Potential founder and President, Dr. Kim Lee Sim.

Dr. Stephen Hoffman, CEO of Sanaria Inc. and a prominent malaria
immunologist who serves as Protein Potential's Chairman notes that, "The
malaria research community has fallen behind in testing the potential of
recombinant protein vaccines to protect against P. vivax infection. Protein
Potential's efforts to develop such a vaccine begin to address this important
issue."

About Protein Potential L.L.C.

Protein Potential's R&D program is focused on vaccine development. The
company has ongoing projects targeting vaccines for infectious diseases like
malaria, and bioterrorism agents including anthrax. Protein Potential's
corporate headquarters, administrative, and R&D operations are located in
Rockville, Maryland. The company's Web site is
www.proteinpotential.com/.

Except for historical information, this news release contains certain
forward-looking statements that involve known and unknown risks and
uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made. These forward-looking statements are further qualified by
important factors that could cause actual results to differ materially from
those in the forward-looking statements.

For further information contact:

Media- Adam Richman +1-301-770-3222, Investors- Robert Thompson
+1-240-403-2750

Adam Richman (media), +1-301-770-3222, or Robert Thompson (investors), +1-240-403-2750, both for Protein Potential LLC